表紙
市場調查報告書
商品編碼
1029575

全球癌症治療生物製藥市場:按技術/地區

Biological Therapies for Cancer: Technologies and Global Markets

出版日期: | 出版商: BCC Research | 英文 258 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,全球癌症治療生物製劑市場預計將以 13.0% 的複合年增長率增長,從 2021 年的 775 億美元增長到 2026 年的 1430 億美元。

按藥物類別,單克隆抗體板塊預計同期復合年增長率為 12.8%,從 2021 年的 680 億美元增長到 2026 年的 1241 億美元。此外,CAR-T 細胞領域預計將以 37.5% 的複合年增長率增長,從 2021 年的 15 億美元增長到 2026 年的 73 億美元。

本報告調查了全球癌症治療生物製劑市場,包括市場定義和概述、臨床概述、流行病學趨勢、主要上市產品、臨床試驗和管道趨勢以及新模型。它總結了冠狀病毒感染 (COVID -19),市場規模的變化/預測,按產品和技術/地區/主要國家,競爭環境,主要公司簡介等細分。

目錄

第 1 章介紹

第 2 章摘要亮點

第 3 章臨床概述

  • 癌症的定義
  • 癌症風險因素/原因
  • 一般癌症治療
  • 癌症的醫療負擔和相關費用

第 4 章癌症類型

  • 肺癌
  • 非小細胞肺癌 (NSCLC)
  • 小細胞肺癌 (SCLC)
  • 其他肺癌
  • 膀胱癌
  • 乳腺癌
  • 宮頸癌
  • 結直腸癌
  • 腎癌
  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 肝癌
  • 黑色素瘤
  • 腦瘤
  • 卵巢癌
  • 前列腺癌
  • 胃癌

第 5 章癌症流行病學

  • 流行病學趨勢:按癌症類型和部位
  • 全球癌症發病率
  • 全球癌症患病率
  • 全球癌症死亡率
  • 流行病學趨勢:按地區

第六章主要推出的產品

  • 單克隆抗體
  • 疫苗
  • CAR-T 細胞療法

第 7 章臨床試驗/管道

  • 癌症臨床試驗概要
  • 主線藥物:按公司分類
  • 主要管線藥物概況
  • Penpulimab

第 8 章 COVID-19 的影響

第 9 章市場分析/預測:按產品/技術

  • 單克隆抗體
  • CAR T細胞療法
  • 癌症疫苗

第 10 章市場分析/預測:按地區

  • 北美
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳大利亞
  • 其他領域

第 11 章市場展望:挑戰/趨勢

  • 醫療保險覆蓋範圍 □ 癌症治療的贖回
  • 癌症生物製劑的定價策略
  • 抗癌藥費用
  • 個性化醫療
  • 生物類似藥概述
  • 生物仿製藥和抗癌藥物的成本
  • 印度和中國的生物仿製藥
  • 生物仿製藥屏障
  • 歐洲生物仿製藥
  • 生物仿製藥的問題
  • 數據保護期
  • 生物製藥和生物仿製藥的區別
  • 生物仿製藥和患者安全

第12章競爭形勢

  • 競爭概覽
  • 競爭份額分析
  • 重大併購
  • 主要許可合同

第 13 章公司簡介

  • AMGEN INC.
  • ASTRAZENECA
  • BRISTOL MYERS SQUIBB
  • ELI LILLY AND CO.
  • GENMAB
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • JANSSEN PHARMACEUTICALS INC.
  • MERCK & CO.
  • NOVARTIS
  • PFIZER INC.
  • ROCHE(F. HOFFMANN-LA ROCHE AG)

第14章 附錄:開頭字母

目錄
Product Code: BIO048D

Highlights:

The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.

The monoclonal antibodies segment of the global cancer biologics market is expected to grow from $68.0 billion in 2021 to $124.1 billion in 2026 at a CAGR of 12.8% for the forecast period of 2021 to 2026.

The CAR T-cell therapy segment of the global cancer biologics market is expected to grow from $1.5 billion in 2021 to $7.3 billion in 2026 at a CAGR of 37.5% for the forecast period of 2021 to 2026.

Report Scope:

This report provides an update on BIO048C Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2026. It discusses important biologics, market share by cancer type, products on the market, market share by company and statistical information for cancer types prevalent globally. It also includes current issues and trends affecting the industry, as well as factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.

The market and sales data for recent years give strong support for research and development (R&D) programs and the move toward biologic treatment for cancer, as well as within biologics toward human monoclonal antibodies, vaccines and CAR T-cell therapies. The biologic drug classes discussed in this report with special focus on cancer treatment are -

  • Monoclonal antibodies.
  • Vaccines.
  • CAR T-cell therapies.

The following approaches to cancer therapeutics are excluded in the report -

  • Chemotherapy.
  • Alkylating agents.
  • Antimetabolites.
  • Cytotoxic agents.
  • Plant derivatives and hormone therapy corticosteroids.
  • Hormone antagonists/antagonists aromatase inhibitors.
  • Radiation therapy.
  • Adjunctive and Supportive therapy.
  • Interferons and Interleukins.
  • Other immunostimulants.
  • Biological therapies for the treatment of other diseases will not be addressed in this report.

The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including -

  • Treatment trends and sales patterns across major cancer indications for U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.
  • Market performance of major pharmaceutical companies.
  • Sales of leading cancer products across major indications from 2018 to 2020.
  • Biosimilars and their impact on currently marketed cancer biotherapeutics.
  • Competitor landscape and share analysis.

This updated report includes the following new information -

  • The latest version of the report provides elaborated information of cancer biologics market at a regional level. The current report provides regional and country-level market segmentation for the U.S., Europe (France, Germany, Italy, Spain, the U.K.), Asia-Pacific (Japan, China, India, and Australia) and the rest of the world.
  • The latest version of the report provides elaborated information of competitor landscape and company share analysis.
  • The latest version of the report also provides elaborated information on the novel CAR T-cell therapies.

Report Includes:

  • 29 data tables and 80 additional tables
  • An updated review of the global markets of biological therapies for cancer treatment and related technologies
  • Analyses of the global market trends, with data from 2020, estimates for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
  • Estimation of the market size and revenue forecast for cancer biologics market and its sub-segments, and corresponding market share analysis by product type, cancer type, and geographic region
  • Coverage of biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products
  • Discussion of biological therapies products available in the market, industry structure, cancer markets in newly emerging therapeutics, and analysis of biosimilars drugs and their impact on the market
  • Review of cancer statistics and epidemiology insights and SWOT analysis of various cancer biotherapeutics present in the market
  • A look at major issues and trends with relate to the R&D of more effective cancer treatment, and new cancer therapeutics in development, and outlook on cancer clinical trials
  • Key marketed drugs and recent approvals, sales statistics and past performance of the top selling biologics, and insight into their patent expiries
  • Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis
  • Descriptive company profiles of the leading market participants, including Amgen Inc., Eli Lilly and Co., GlaxoSmithKline, Merck & Co. Inc., and Pfizer Inc.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • What's New in This Update
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Clinical Overview

  • Definition of Cancer
  • Risk Factors for and Causes of Cancer
  • Tobacco Use
  • Alcohol Abuse and Cancer Statistics
  • Obesity and Cancer Statistics
  • Infectious Diseases and Cancer
  • Inherited Genes: Diseases and Cancer
  • Sun, Ultraviolet Radiation and Cancer
  • Hormones and Cancer
  • Overview of Common Cancer Treatments
  • Surgery
  • Chemotherapy
  • Radiation Therapy
  • Hormone Therapy
  • Targeted Therapy and Immunotherapy
  • Overview of Cancer Burden and Related Costs

Chapter 4 Cancer Types

  • Lung Cancer
  • Overview
  • Non-small-Cell Lung Cancer (NSCLC)
  • Small-Cell Lung Cancer (SCLC)
  • Other Lung Cancers
  • Treatments
  • Bladder Cancer
  • Overview
  • Treatments
  • Breast Cancer
  • Overview
  • Common Breast Cancer Mutations
  • Treatments
  • Cervical Cancer
  • Overview
  • Treatments
  • Colorectal Cancer
  • Overview
  • Treatments
  • Kidney Cancer
  • Treatments
  • Leukemia
  • Overview
  • Treatment
  • Lymphoma
  • Overview
  • Treatment
  • Multiple Myeloma
  • Overview
  • Treatments
  • Liver Cancer
  • Overview
  • Treatments
  • Melanoma
  • Overview
  • Treatments
  • Brain Cancer
  • Overview
  • Treatments
  • Ovarian Cancer
  • Treatments
  • Prostate Cancer
  • Treatments
  • Stomach Cancer

Chapter 5 Cancer Epidemiology

  • Epidemiology by Cancer Type/Site
  • Global Cancer Incidence
  • Global Cancer Prevalence, 2020
  • Global Cancer Mortality Overview
  • Cancer Epidemiology by Region
  • Europe
  • North America
  • Asia-Pacific
  • Rest of the World

Chapter 6 Key Marketed Products

  • Current Drugs and Recent Approvals
  • Monoclonal Antibodies
  • Vaccines
  • CAR T-Cell Therapies
  • Sales Statistics of Selected Key Biologics

Chapter 7 Cancer Clinical Trials and Pipeline Biologics

  • Overview of Cancer Clinical Trials
  • Key Pipeline Drugs by Company
  • Key Pipeline Drug Profiles
  • Penpulimab

Chapter 8 Impact of COVID-19 Pandemic on the Market for Cancer Biologics

  • Overview
  • Current Outlook
  • Impact of COVID-19 on Cancer Care
  • Delay in Elective Surgical Procedures
  • Trade Restrictions and Supply Disruptions

Chapter 9 Market Breakdown by Product and Technology

  • Monoclonal Antibodies
  • Market Overview
  • Market Size and Forecast
  • Market Segmentation by Geography
  • CAR T-Cell Therapy
  • Market Overview
  • Market Size and Forecast Analysis
  • Market Segmentation by Geography
  • Cancer Vaccines
  • Market Overview
  • Market Size and Forecast Analysis
  • Market Segmentation by Geography

Chapter 10 Market Breakdown by Region

  • Global Market Overview
  • North America
  • United States
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of the World

Chapter 11 Cancer Biologics Market Outlook: Issues and Trends

  • Medicare Coverage and Reimbursement for Cancer Care
  • Pricing Strategies for Cancer Biologics
  • Cancer Drug Costs
  • Personalized Medicine
  • Overview of Biosimilars
  • Biosimilars and Costs of Cancer Drugs
  • Biosimilars in India and China
  • Hurdles For Biosimilars
  • Biosimilars in Europe
  • Issues with Biosimilars
  • Data Exclusivity Periods
  • Differences Between Biopharmaceuticals and Biogenerics
  • Biosimilars and Patient Safety

Chapter 12 Competitive Landscape

  • Competitive Overview
  • Competitive Share Analysis
  • Key Merger and Acquisitions in the Global Cancer Market
  • Key Licensing Deals in Global Cancer Market

Chapter 13 Company Profiles

  • AMGEN INC.
  • ASTRAZENECA
  • BRISTOL MYERS SQUIBB
  • ELI LILLY AND CO.
  • GENMAB
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • JANSSEN PHARMACEUTICALS INC.
  • MERCK & CO.
  • NOVARTIS
  • PFIZER INC.
  • ROCHE (F. HOFFMANN-LA ROCHE AG)

Chapter 14 Appendix: Acronyms

List of Tables

  • Summary Table A : Global Market for Cancer Biologics, by Product Type, Through 2026
  • Summary Table B : Global Market for Cancer Biologics, by Region, Through 2026
  • Table 1 : Global High BMI-Related Cancer Deaths and DALYs, 2017
  • Table 2 : National Expenditure Estimates for Cancer Care, by Cancer Type, 2015 vs. 2020
  • Table 3 : NSCLC Treatments
  • Table 4 : SCLC Treatments
  • Table 5 : Bladder Cancer Treatments
  • Table 6 : Breast Cancer Treatments
  • Table 7 : Cervical Cancer Treatments
  • Table 8 : Colorectal Cancer Treatments
  • Table 9 : Kidney Cancer Treatments
  • Table 10 : Leukemia Treatments
  • Table 11 : NHL Treatments
  • Table 12 : Multiple Myeloma Treatments
  • Table 13 : Liver Cancer Treatments
  • Table 14 : Melanoma Treatments
  • Table 15 : Brain Cancer Treatments
  • Table 16 : Ovarian Cancer Treatments
  • Table 17 : Prostate Cancer Treatments
  • Table 18 : Stomach Cancer Treatments
  • Table 19 : Global Cancer Incidence, by Cancer Type/Site, 2020
  • Table 20 : Global Cancer Mortality, by Cancer Type/Site, 2020
  • Table 21 : Estimated Number of New Cancer Cases in the U.S., by Cancer Type/Site and Sex, 2021
  • Table 22 : Estimated Number of Cancer Deaths in the U.S., by Cancer Type/Site and Sex, 2021
  • Table 23 : Comprehensive List of FDA-Approved Monoclonal Antibodies
  • Table 24 : Rituxan (Rituximab) Drug Profile
  • Table 25 : Avastin Drug Profile
  • Table 26 : Herceptin Drug Profile
  • Table 27 : Erbitux Drug Profile
  • Table 28 : Erbitux Approvals, by Year
  • Table 29 : Opdivo Drug Profile
  • Table 30 : Opdivo: Recent FDA Approvals and Regulatory Updates
  • Table 31 : Keytruda: Recent FDA Approvals and Regulatory Updates
  • Table 32 : Darzalex Drug Profile
  • Table 33 : Darzalex: FDA Approvals and Regulatory Updates
  • Table 34 : Perjeta Drug Profile
  • Table 35 : Imfinzi Drug Profile
  • Table 36 : Tecentiq Drug Profile
  • Table 37 : Tecentriq: FDA Approvals and Regulatory Updates
  • Table 38 : Xgeva Drug Profile
  • Table 39 : Kadcyla Drug Profile
  • Table 40 : Yervoy Drug Profile
  • Table 41 : Yervoy: Recent FDA Approvals and Regulatory Updates
  • Table 42 : Trodelvy Drug Profile
  • Table 43 : Blenrep Drug Profile
  • Table 44 : Jemperli Drug Profile
  • Table 45 : Zynlonta Drug Profile
  • Table 46 : Rybrevant Drug Profile
  • Table 47 : Sarclisa Drug Profile
  • Table 48 : Phesgo Drug Profile
  • Table 49 : Monjuvi Drug Profile
  • Table 50 : Provenge Drug Profile
  • Table 51 : Provenge: Key Product Highlights
  • Table 52 : Gardasil/Gardasil 9 Drug Profile
  • Table 53 : Gardasil/Gardasil 9: FDA-Approved Cancer Indications by Sex
  • Table 54 : Sales Statistics of Key Cancer Biologics, by Leading Manufacturers, 2018-2020
  • Table 55 : Number of Clinical Trials, by Cancer Type/Site and Phase, 2021
  • Table 56 : List of Selected Key Pipeline Cancer Biologics
  • Table 57 : Penpulimab Drug Profile
  • Table 58 : Sintilimab (Tyvyt) Drug Profile
  • Table 59 : Toripalimab Drug Profile
  • Table 60 : Tisotumab Vedotin Drug Profile
  • Table 61 : Retifanlimab Drug Profile
  • Table 62 : Glofitamab Drug Profile
  • Table 63 : Tiragolumab Drug Profile
  • Table 64 : Mosunetuzumab Drug Profile
  • Table 65 : Canakinumab Drug Profile
  • Table 66 : Datopotamab Deruxtecan Drug Profile
  • Table 67 : Reported COVID-19 Cases and Deaths, by Country, May 2021
  • Table 68 : Global Market for Cancer Biologics, by Product Type, Through 2026
  • Table 69 : List of Key Target Sites for Monoclonal Antibodies
  • Table 70 : Global Market for Monoclonal Antibodies to Treat Cancer, by Region, Through 2026
  • Table 71 : Global Market for CAR T-Cell Therapy for Cancer, by Region, Through 2026
  • Table 72 : Global Market for Cancer Vaccines, by Region, Through 2026
  • Table 73 : Global Market for Cancer Biologics, by Region, Through 2026
  • Table 74 : North American Market for Cancer Biologics, by Product Type, Through 2026
  • Table 75 : Key FDA Approved Novel Biologics, 2020 and 2021
  • Table 76 : Canada: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
  • Table 77 : Key EMA Approved Novel Biologics, 2020 and 2021
  • Table 78 : European Market for Cancer Biologics, by Product Type, Through 2026
  • Table 79 : U.K.: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 80 : Germany: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 81 : France: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 82 : Italy: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 83 : Spain: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 84 : Asia-Pacific Market for Cancer Biologics, by Product Type, Through 2026
  • Table 85 : Japan: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
  • Table 86 : Key Approved Novel Cancer Biologics by Japanese MHLW, 2020-2021
  • Table 87 : China: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 88 : Key Approved Novel Cancer Biologics by Chinese NMPA, 2019 and 2020
  • Table 89 : India: Cancer Incidence and Mortality, by Cancer Type/Site, 2020
  • Table 90 : Australia: Cancer Incidence, Mortality and Survival Estimates, by Cancer Type/Site, 2020
  • Table 91 : Rest of the World Market for Cancer Biologics, by Product Type, Through 2026
  • Table 92 : Key Federal Health Insurance Programs in the U.S.
  • Table 93 : Top Mergers and Acquisitions in the Global Cancer Therapeutics Market, 2019-2020
  • Table 94 : Top Licensing Deals of Cancer Drugs, 2019-2020
  • Table 95 : Amgen: Key Cancer Biologics Product Portfolio
  • Table 96 : AstraZeneca: Key Cancer Biologics Product Portfolio
  • Table 97 : Bristol Myers Squibb: Key Cancer Biologics Product Portfolio
  • Table 98 : Eli Lilly and Co.: Key Cancer Biologics Product Portfolio
  • Table 99 : Genmab: Key Cancer Biologics Product Portfolio
  • Table 100 : Gilead Sciences: Key Cancer Biologics Product Portfolio
  • Table 101 : GlaxoSmithKline: Key Cancer Biologics Product Portfolio
  • Table 102 : Janssen Pharmaceuticals: Key Cancer Biologics Product Portfolio
  • Table 103 : Merck& Co.: Key Cancer Biologics Product Portfolio
  • Table 104 : Novartis: Key Cancer Biologics Product Portfolio
  • Table 105 : Pfizer Inc.: Key Cancer Biologics Product Portfolio
  • Table 106 : Roche: Key Cancer Biologics Product Portfolio
  • Table 107 : Acronyms Used in This Report

List of Figures

  • Summary Figure A : Global Market Shares of Cancer Biologics, by Product Type, 2020
  • Summary Figure B : Global Market Shares of Cancer Biologics, by Region, 2020
  • Figure 1 : Global Tobacco Consumption Population, by Sex and Country, 2019
  • Figure 2 : Global Incidence of Alcohol-Attributable Cancers, by Cancer Type and Sex
  • Figure 3 : Share of Diagnosed Population of Infections-Attributable to Cancers, by Type, 2018
  • Figure 4 : Cancers Attributable to UV Radiation Exposure, by Region and Age Group, 2012
  • Figure 5 : Productivity Losses Due to Cancer Attributed to Premature Deaths in Emerging Economies, 2017
  • Figure 6 : U.S. National Cancer Costs, Projections and Trends, 2015-2030
  • Figure 7 : Global Cancer Incidence, by Sex and Cancer Type/Site, 2020
  • Figure 8 : Global Cancer Incidence, by Region, 2020
  • Figure 9 : Global Cancer Incidence Trends, by Cancer Type/Site, 2020-2030
  • Figure 10 : Global Cancer Prevalence by Cancer Type/Site and Sex, 2020
  • Figure 11 : Avastin: Global Product Revenue, 2018-2020
  • Figure 12 : Herceptin: Global Product Revenue, 2018-2020
  • Figure 13 : Erbutix: Global Product Revenue, 2019 and 2020
  • Figure 14 : Opdivo: Global Product Revenue, 2018-2020
  • Figure 15 : Keytruda: Global Product Revenue, 2018-2020
  • Figure 16 : Darzalex: Global Product Revenue, 2018-2020
  • Figure 17 : Perjeta: Global Product Revenue, 2018-2020
  • Figure 18 : Imfinzi: Global Product Revenue, 2018-2020
  • Figure 19 : Tecentriq: Global Product Revenue, 2018-2020
  • Figure 20 : Xgeva: Global Product Revenue, 2018-2020
  • Figure 21 : Kadcyla: Global Product Revenue, 2018-2020
  • Figure 22 : Yervoy: Global Product Revenue, 2018-2020
  • Figure 23 : Gardasil and Cervarix: Comparative Global Sales Trend, 2010-2020
  • Figure 24 : Heplisav-B: Global Net Product Revenue, 2018-2020
  • Figure 25 : Global Market Shares of Cancer Biologics, by Product Type, 2020
  • Figure 26 : Global Market for Cancer Monoclonal Antibodies, 2020-2026
  • Figure 27 : Number of Approved Cancer Monoclonal Antibodies, by Year, 2010-2020
  • Figure 28 : Comparison of Approved Indications for Matrix to CAR T-Cell Therapies
  • Figure 29 : Global Market for CAR T-Cell Therapies, 2020-2026
  • Figure 30 : Product Revenue of Key CAR T-Cell Therapy (Yescarta), by Region, 2018-2020
  • Figure 31 : Global Market for Cancer Vaccines, 2020-2026
  • Figure 32 : Global Market for Cancer Biologics, by Region, 2020-2026
  • Figure 33 : North American Market Shares of Cancer Biologics, by Product Type, 2020
  • Figure 34 : U.S. Market for Cancer Biologics, 2020-2026
  • Figure 35 : U.S. Leading Sites of New Cancer Incidence and Deaths, 2021
  • Figure 36 : Canadian Market for Cancer Biologics, 2020-2026
  • Figure 37 : European Market Shares of Cancer Biologics, by Product Type, 2020
  • Figure 38 : U.K. Market for Cancer Biologics, 2020-2026
  • Figure 39 : German Market for Cancer Biologics, 2020-2026
  • Figure 40 : French Market for Cancer Biologics, 2020-2026
  • Figure 41 : Italian Market for Cancer Biologics, 2020-2026
  • Figure 42 : Spanish Market for Cancer Biologics, 2020-2026
  • Figure 43 : Asia-Pacific Market Shares of Cancer Biologics, by Product Type, 2020
  • Figure 44 : Japanese Market for Cancer Biologics, 2020-2026
  • Figure 45 : Chinese Market for Cancer Biologics, 2020-2026
  • Figure 46 : Indian Market for Cancer Biologics, 2020-2026
  • Figure 47 : Australian Market for Cancer Biologics, 2020-2026
  • Figure 48 : Distribution of Cancer Care Spending in the U.S., by Treatment Cost, 2018
  • Figure 49 : Illustration of Traditional vs. PPM Based Model for Cancer Treatment
  • Figure 50 : Global Market Shares of Cancer Biologics, by Manufacturer, 2020
  • Figure 51 : Amgen: Annual Revenue, 2016-2020
  • Figure 52 : AstraZeneca: Annual Revenue, 2016-2020
  • Figure 53 : Bristol Myers Squibb: Annual Revenue, 2016-2020
  • Figure 54 : Bristol Myers Squibb: Revenue Share, by Geography, 2016-2020
  • Figure 55 : Eli Lilly and Co.: Annual Revenue, 2016-2020
  • Figure 56 : Eli Lilly and Co.: Revenue Share, by Therapy Area, 2020
  • Figure 57 : Genmab: Annual Revenue, 2016-2020
  • Figure 58 : Gilead Sciences: Annual Revenue, 2016-2020
  • Figure 59 : GlaxoSmithKline: Annual Revenue, 2016-2020
  • Figure 60 : GlaxoSmithKline: Revenue Share, by Business Segment, 2020
  • Figure 61 : Johnson & Johnson: Annual Revenue, 2016-2020
  • Figure 62 : Johnson & Johnson: Revenue Share, by Segment, 2020
  • Figure 63 : Merck & Co.: Annual Revenue, 2016-2020
  • Figure 64 : Novartis: Annual Revenue, 2016-2020
  • Figure 65 : Pfizer Inc.: Annual Revenue, 2016-2020
  • Figure 66 : Pfizer Inc.: Annual Revenue Share, by Geography, 2018-2020
  • Figure 67 : Roche: Annual Revenue, 2016-2020
  • Figure 68 : Roche: Revenue Share, by Therapy Area (Pharma Division), 2020